Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 52, 2017 - Issue 2
Submit an article Journal homepage
292
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy

Ashley BondDepartment of Gastroenterology, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK;
,
Susanna DoddDepartment of Biostatistics, University of Liverpool, Liverpool, UK
,
Gareth FisherDepartment of Gastroenterology, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK;
,
Thomas SkourasDepartment of Gastroenterology, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK;
&
Sreedhar SubramanianDepartment of Gastroenterology, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK; Correspondence[email protected]
Pages 204-208 | Received 10 Aug 2016, Accepted 01 Oct 2016, Published online: 31 Oct 2016

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Raffaella Franca, Debora Curci, Marianna Lucafò, Giuliana Decorti & Gabriele Stocco. (2019) Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opinion on Drug Metabolism & Toxicology 15:7, pages 527-539.
Read now

Articles from other publishers (7)

Francisco Rodríguez-Moranta, Federico Argüelles-Arias, Joaquín Hinojosa del Val, Marisa Iborra Colomino, M. Dolores Martín-Arranz, Luis Menchén Viso, Fernando Muñoz Núñez, Elena Ricart Gómez, José Germán Sánchez-Hernández, Teresa Valdés-Delgado, Jordi Guardiola Capón, Manuel Barreiro-de Acosta, Míriam Mañosa Ciria, Yamile Zabana Abdo & Ana Gutiérrez Casbas. (2024) Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Gastroenterología y Hepatología.
Crossref
Alessandra Vultaggio, Margherita Perlato, Francesca Nencini, Emanuele Vivarelli, Enrico Maggi & Andrea Matucci. (2021) How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?. Frontiers in Immunology 12.
Crossref
Jake S. JasurdaRobert P. McCabe & Byron P. Vaughn. (2021) Adalimumab Concentration Changes After Dose Escalation in Inflammatory Bowel Disease. Therapeutic Drug Monitoring 43:5, pages 645-651.
Crossref
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu’Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger, Kevin J Barrett, R Justin Davies, Cathy Bennett, Stuart Gittens, Malcolm G Dunlop, Omar Faiz, Aileen Fraser, Vikki Garrick, Paul D Johnston, Miles Parkes, Jeremy Sanderson, Helen Terry, Daniel R Gaya, Tariq H Iqbal, Stuart A Taylor, Melissa Smith, Matthew Brookes, Richard Hansen & A Barney Hawthorne. (2019) British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68:Suppl 3, pages s1-s106.
Crossref
Evan D Elias, Laura E Targownik, Harminder Singh & Charles N Bernstein. (2019) A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD. Inflammatory Bowel Diseases.
Crossref
Bella Ungar, Tal Engel, Doron Yablecovitch, Adi Lahat, Alon Lang, Benjamin Avidan, Ofir Har-Noy, Dan Carter, Nina Levhar, Limor Selinger, Sandra Neuman, Ola Haj Natour, Miri Yavzori, Ella Fudim, Orit Picard, Uri Kopylov, Yehuda Chowers, Timna Naftali, Efrat Broide, Eyal Shachar, Rami Eliakim & Shomron Ben-Horin. (2018) Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study. American Journal of Gastroenterology 113:6, pages 890-898.
Crossref
Rikke B. Holmstrøm, Ditte V. Mogensen, Jørn Brynskov, Mark A. Ainsworth, Jacob Nersting, Kjeld Schmiegelow & Casper Steenholdt. (2018) Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences 63:6, pages 1583-1591.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.